Compare Globus Medical Inc. Class A Common Stock (GMED) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Xpeng Inc - ADR — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Xpeng Inc - ADR trades at $9.44 (market cap $9.24B). The key difference: Globus Medical Inc. Class A Common Stock and Xpeng Inc - ADR are close in size by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Xpeng Inc - ADR for 81 Days on average.
| GMED | XPEV | |
|---|---|---|
Market Cap | $10.25B | $9.24B |
Volume | 1,108,124 | 6,669,510 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $28.07 |
52-Week Low | $58.33 | $9.25 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $9.76B | $11.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
XPeng (XPEV) trades at $9.42, down 2.48% amid bearish technical signals despite strong revenue growth. The company delivered 41,256 vehicles in September 2026 and is expanding globally with new model launches. While revenue surged to $76.72 billion in 2025, net losses persist at -$1.14 billion, though margins are improving. Analyst consensus remains bullish with a $17.55 price target.
Investment outlook balances growth potential against profitability challenges. XPeng's expansion into AI robotics and European markets offers upside, but persistent losses and competitive pressures pose risks. The stock presents a speculative opportunity for investors betting on future profitability and market share gains in the evolving EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
